GSK’s (GSK) “Underweight” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their underweight rating on shares of GSK (LON:GSK) in a research note published on Thursday, Marketbeat Ratings reports.

Several other equities research analysts have also recently commented on GSK. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 1,600 price objective on shares of GSK in a research report on Friday, July 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,450 price objective on shares of GSK in a research report on Thursday, July 31st. Finally, Shore Capital reiterated a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a report on Monday, October 20th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, GSK presently has an average rating of “Hold” and an average price target of GBX 1,637.50.

GSK Price Performance

LON GSK opened at GBX 1,620 on Thursday. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The stock has a market cap of £65.20 billion, a price-to-earnings ratio of 19.59, a PEG ratio of 1.24 and a beta of 0.31. The business has a 50 day simple moving average of GBX 1,534.78 and a 200 day simple moving average of GBX 1,453.63. GSK has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 1,684.50.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, July 30th. The company reported GBX 75.30 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity at GSK

In related news, insider Wendy Becker acquired 526 shares of the firm’s stock in a transaction dated Friday, September 19th. The stock was bought at an average price of GBX 1,503 per share, for a total transaction of £7,905.78. In the last three months, insiders have bought 576 shares of company stock worth $865,799. Corporate insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.